Off-the-shelf allogeneic cell therapy to fight cancer

Sakura Bio is a start-up company developing an off-the-shelf, allogeneic T-cell therapy to fight cancer.

Our lead product, Skill-T (Super Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. 

The technology was established by Professor Amnon Peled and Dr. Inbal Mishalian at Hadassah Medical Center, and involves a simple, cost effective, proprietary manufacturing process.

 

In contrast to other T-cell based products, such as CAR-T, Skill-T cells have High safety profile, with no Graft-versus-host disease (GVHD), and can be developed as an off-the-shelf T cell product.

 

Skill-T cells have demonstrated promising in vitro and in vivo efficacy against both hematological malignancies and solid tumors in various model systems, including mouse xenograft models for Ovarian cancer and Acute Myeloid Leukemia (AML). Comparative studies highlight the superior activity of Skill-T cells over other PBMC-derived approaches.

 

Sakura Bio has established and optimized a scaled-up manufacturing process and an efficient cryopreservation protocol for Skill-T that ensures a high recovery yield of an effective product. We are now progressing towards a Phase I clinical trial for Skill-T, aiming to confirm its potential as a transformative off-the-shelf cell therapy product.